Mads Krogsgaard Thomsen

Last updated

Mads Krogsgaard Thomsen
BornDecember 27, 1960
CitizenshipDanish
EducationDVM, DSc and PhD
EmployerNovo Nordisk Foundation
TitleCEO of Novo Nordisk Foundation
Board member ofTechnical University of Denmark (DTU), University of Copenhagen
HonoursKnight of Order of the Dannebrog

Mads Krogsgaard Thomsen (born December 27, 1960) is a Danish businessman, CEO of the Novo Nordisk Foundation [1] [2] [3] and former Executive Vice President of Research & Development, head of R&D and Chief Scientific Officer (CSO) at the pharmaceutical company Novo Nordisk. [4]

Contents

Education and background

Mads Krogsgaard Thomsen went to boarding school in Epsom, Surrey in Great Britain from 1967 to 1971. He graduated from high school from Rungsted Stateside in 1979. He holds a master's degree from The Royal Veterinary and Agricultural University in 1986, now part of the University of Copenhagen. According to Krogsgaard Thomsen himself, he originally wanted to be a practicing veterinarian, and was inspired by the British television series All Creatures Great And Small. [5] At the Royal Veterinary and Agricultural University, however, he started to take an interest in pursuing a career in either science or the pharmaceutical industry. He finished his PhD. from the same university in 1991.

Career

Mads Krogsgaard Thomsen was employed by Novo Nordisk in 1991 as head of Growth Hormone Research and became Executive Vice President for Diabetes R&D in 1994. He was appointed senior vice president of Diabetes R&D in 1994.

In November 2000, he was appointed executive vice president and Chief Scientific Officer (CSO). [4] From 1994 to 2021 he was responsible for the research and development of 20 medical products specifically within diabetes treatment and the development of GLP-1 and tablet technology used as a replacement for conventional injection-based technology in biological diabetes treatment. He left the position as Senior Vice President of R&D on February 28 in 2021 and took the role as CEO of the Novo Nordisk Foundation on March 1, 2021. [1]

From 2017 to 2019, Thomsen was the chairman of the board of directors at University of Copenhagen. Mads Krogsgaard Thomsen received the royal decoration of Knight of the Order of the Dannebrog by the Danish Royal House on 12 December, 2022. [6]

In 2024, Thomsen received the Golden Plate Award of the American Academy of Achievement, presented by Awards Council member Robert S. Langer. [7]

Personal life

Mads Krogsgaard Thomsen is married to Ulla. Mads has three children from previous marriages. [8]

Related Research Articles

<span class="mw-page-title-main">University of Copenhagen Faculty of Health and Medical Sciences</span>

The Faculty of Health and Medical Sciences at the University of Copenhagen houses 13 departments, 33 centres, five schools, four hospitals, and three libraries.

<span class="mw-page-title-main">Novo Nordisk</span> Danish pharmaceutical company

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd with production facilities in nine countries and affiliates or offices in five countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28% of its shares and a majority (77%) of its voting shares.

<span class="mw-page-title-main">Hans Christian Hagedorn</span>

Hans Christian Hagedorn was the creator of NPH insulin and the founder of Nordisk Insulinlaboratorium, which is known today as Novo Nordisk.

<span class="mw-page-title-main">Team Novo Nordisk</span> American cycling team

Team Novo Nordisk is an all-diabetic professional cycling team founded by CEO Phil Southerland and led by general manager Vassili Davidenko. It is headquartered in Atlanta, Georgia.

The Robert Award for Best Actor in a Leading Role is a Danish Film Academy award presented at the annual Robert Award ceremony to recognize an actor who has delivered an outstanding leading performance in a Danish film.

<span class="mw-page-title-main">Novo Holdings A/S</span> Danish holding company

Novo Holdings A/S is the Novo Nordisk Foundation's wholly owned holding company for Novo Nordisk A/S and Novozymes A/S. Novo Holdings A/S was established in 1999 and manages the Novo Nordisk Foundation's assets, which in 2023 was worth almost DKK 1,114 billion Danish Kroner. The company generated a total income and investment return of DKK 31 billion in 2023.

Lise Kingo is a Danish businesswoman who currently serves as Independent Board Director at Danone, Sanofi and Covestro. Kingo is also a member of the Advisory Board for Humanitarian and Development Aid at the Novo Nordisk Foundation.

<span class="mw-page-title-main">Semaglutide</span> Anti-diabetic and anti-obesity medication

Semaglutide is an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management. It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain. It can be administered by subcutaneous injection or taken orally. It is sold under the brand names Ozempic and Rybelsus for diabetes, and under the brand name Wegovy for weight loss.

<span class="mw-page-title-main">Novo Nordisk Foundation</span> International foundation for medical treatment and research

The Novo Nordisk Foundation is an international enterprise foundation focusing on medical treatment and research.

<span class="mw-page-title-main">Kåre Schultz</span> Danish business executive (born 1961)

Kåre Schultz is a Danish business executive. Was the chief executive officer of Teva Pharmaceutical Industries between September 2017 and December 2022.

<span class="mw-page-title-main">Jesper Møller (mathematician)</span> Danish mathematician (born 1957)

Jesper Møller is a Danish mathematician.

Christian S. Jensen is a Danish computer scientist who is a professor at Aalborg University.

<span class="mw-page-title-main">Lars Rebien Sørensen</span> Danish businessman (born 1954)

Lars Rebien Sørensen is a Danish businessman and former CEO of the pharmaceutical company Novo Nordisk and current chairman of the board at the Novo Nordisk Foundation and Novo Holdings A/S.

<span class="mw-page-title-main">Kristian Pihl Lorentzen</span> Danish politician

Kristian Pihl Lorentzen is a Danish politician and author, who is a former member of the Folketing for the Venstre political party. He was elected into parliament at the 2005 Danish general election.

<span class="mw-page-title-main">Thomas Sinkjær</span> Danish scientist (born 1958)

Thomas Sinkjær R is a Danish scientist and professor of neuroscience and technology at the Department of Health Science and Technology of Aalborg University, Denmark. He is the Secretary General of the Royal Danish Academy of Sciences and Letters and an elected fellow of the Danish Academy of Technical Sciences.

<span class="mw-page-title-main">Lars Fruergaard Jørgensen</span> Danish businessman (born 1966)

Lars Fruergaard Jørgensen is a Danish businessman, the Chief Executive of Novo Nordisk since January 2017 and Chairman of the European Federation of Pharmaceutical Industries and Associations.

The Novo Nordisk Prize is an annual award presented to acknowledge exceptional contributions within the fields of medical and health sciences. It is specifically aimed at individuals who have demonstrated outstanding research or innovation that has the potential to advance medical science, particularly in areas related to diabetes, endocrinology, and biopharmaceutical science. The prize is administered by the Novo Nordisk Foundation, an independent Danish enterprise foundation.

The Hagedorn Prize is an annual award within the field of medical research, specifically recognizing outstanding contributions to diabetes research and endocrinology. Named after Hans Christian Hagedorn, a renowned Danish scientist and co-founder of Nordisk Insulinlaboratorium, the prize celebrates achievements in the understanding and treatment of diabetes.

Lotte Bjerre Knudsen is a Danish scientist and university professor. She led the development of liraglutide and oversaw the development of semaglutide, two notable drugs approved for indications in the treatment of diabetes and obesity.

Arne Vernon Astrup is a Danish nutritionist, chief physician, researcher, author and professor. He is known as a researcher, communicator and author and has published more than 900 scientific articles. In 2018 he was internationally recognised as one of the world's most cited researchers. Arne Astrup has contributed to the identification of GLP-1 as a satiety hormone, which has played a key role in the development of GLP-1 drugs for the treatment of obesity, which has contributed to the success of Novo Nordisk A/S and their drug Wegovy.

References

  1. 1 2 Mostrup, Christian (February 3, 2021). "Mads Krogsgaard Thomsen appointed as new CEO of the Novo Nordisk Foundation". Novo Nordisk Fonden.
  2. ↑ Heimer, Hakon (February 24, 2021). "Leadership Change at Novo Nordisk Foundation | Nordic Society for Precision Medicine". nshg-pm.org. Retrieved May 27, 2021.
  3. ↑ "New CEO of the Novo Nordisk Foundation". european-biotechnology.com. February 24, 2021. Retrieved May 27, 2021.
  4. 1 2 "Mads Krogsgaard Thomsen". sciencenews.dk (in Danish). Retrieved May 27, 2021.
  5. ↑ Friis, Rasmus (March 3, 2022). "Det hele faldt på plads for Mads Krogsgaard på andet semester". Uniavisen. Retrieved July 6, 2022.
  6. ↑ (Danish) - Overview of recipients of Danish decorations: https://www.kongehuset.dk/monarkiet-i-danmark/ordener-og-medaljer/modtagere-af-danske-dekorationer/#oversigt-over-modtagere-af-danske-dekorationer
  7. ↑ "Golden Plate Awardees of the American Academy of Achievement". achievement.org. American Academy of Achievement.
  8. ↑ Mortensen, Thomas Mikkel (October 5, 2019). "Efter ti års fejlslagen forskning fik Mads en dristig idé: Nu har Novo ramt en guldåre". Berlingske.dk (in Danish). Retrieved May 27, 2021.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.